New Cancer Markers

Duffy, Michael J.

doi:10.1177/000456328902600501

Cited by 22 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longitudinal studies of healthy woman have demonstrated the statistical significance of this marker to monitor breast cancer patients (3). Several studies show that cancer markers often detect metastasis before a clinical manifestation (5,6). It has been determined that a number of tumor markers are present in saliva therefore its use as a diagnostic fluid could have significant diagnostic and logistical advantages when compared to serum (1).…”

Section: Introductionmentioning

confidence: 99%

Correlation of serum and salivary CA15-3 levels in patients with breast cancer

Agha‐Hosseini

Mirzaii‐Dizgah²,

Rahimi³

2009

Med Oral

View full text Add to dashboard Cite

Objectives: The aim of this study was to assess the relationship between serum and saliva levels of cancer antigen (CA) 15-3 and to compare them between women with and without breast cancer. Study design: A case-control study was carried out on 61 women aged 28-69 years, including women with and without breast cancer (26 as part of the case study and 35 as part of the control group) conducted at the Emam Khomeini Hospital, Tehran University of Medical Sciences. CA15-3 levels were assayed in serum and unstimulated whole saliva by EIA. Unpaired t-test, one-way ANOVA and Pearson correlation were used as statistical analysis. Results: The salivary and serological levels of CA15-3 in the cancer patients were significantly higher (P <0.01) than the salivary and serum levels of healthy controls. They were also higher in stage 2 than in stage 1 in cancer patients. However, the saliva flow rate was significantly lower in the cancer patients (P <0.01). There was a significant positive correlation between serum and saliva CA15-3 concentration (r = 0.614) and also between serum concentration and saliva output of CA15-3 (r = 0.541). Conclusion: The results of the study suggest that salivary CA15-3 may have potential use in the initial detection of breast cancer in women.

show abstract

Section: Introductionmentioning

confidence: 99%

Correlation of serum and salivary CA15-3 levels in patients with breast cancer

Agha‐Hosseini

Mirzaii‐Dizgah²,

Rahimi³

2009

Med Oral

View full text Add to dashboard Cite

show abstract

“…Clearly, there is a need for new diagnostic and predictive factors to be able to choose the correct therapy and also to limit the treatment load given to each patient. Several studies show that cancer markers often detect metastasis before a clinical manifestation [3,4]. Numerous reports show that the immunoassays CA 15-3 and CEA are useful for breast cancer patients [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Elevated CA 125 in Breast Cancer – A Sign of Advanced Disease

Norum¹,

Erikstein²,

Nustad³

2001

Tumor Biol

View full text Add to dashboard Cite

The serum tumor markers CA 125, MUC1 and CEA were measured in 221 breast cancer patients over a period of 2 years. Patients examined on at least three occasions were included in the study. Thirty-three patients had increasing or continuously high concentrations of CA 125. Thirty (91%) of these had involvement of the pleura, either as pleural metastasis or metastasis in surrounding tissue i.e. bone structures in the thorax cavity or lung parenchyma. MUC1 and CEA were elevated in 27 (82%) and 24 (73%) of the 33 patients, respectively. Increased concentrations of these two markers did not relate to the site of metastasis. However, the three tumor markers complemented each other in detecting early metastases. Increased CA 125 was associated with metastasis in or near the pleura, and in stage IV breast cancer it was related to poor prognosis.

show abstract

“…The most recently discovered breast cancer antigen is CA 15-3, which has been identified by reaction with two monoclonal antibodies (4). In clinical studies (5-7), it was found to detcct breast carcinoma metastases with higher sensitivity than the most widely used marker carcinoembryonic antigen (CEA).…”

mentioning

confidence: 99%